Fig 1: Schematic diagram of the whole experimental workflow. The whole experimental workflow consists of the PCSK9 immunization, blood sampling, VHH library construction, E. coli transformation, phage-display panning, Sanger sequencing, VHHs protein expression, bivalent VHH design, affinity test, LDL-uptake, and pharmacodynamics assay
Fig 2: The epitope binning assay by SPR and ELISA. a The epitope binning assay of the VHH-B11 was performed against the approved evolocumab by SPR (Protein A chip). The horizontal axis represents the timeline. The vertical axis represents the relative response unit. The curve consists of four processes: baseline; capture evolocumab; injecting PCSK9 (binding and dissociation); injecting VHH-B11 (binding and dissociation). b The dual antibody sandwich ELISA method between VHH-B11 and the approved evolocumab (coated on the plate, as shown in the schematic diagram). The horizontal axis represents different dilution concentrations of the VHH-B11. The vertical axis represents the OD450 value
Supplier Page from Sino Biological, Inc. for Human PCSK9 / NARC1 Protein (Fc Tag)